OXYGEN
24/05/2005, 10h33
Genentech drug maker reports early trail data shows Lucentis effective in AMD eyesight restoration.
05/22/05 22:56 PM, EDT
Genentech Inc. said data from a Phase III clinical study showed that its investigational drug Lucentis maintained or improved vision in patients with wet age-related macular degeneration, which causes vision loss.
(...)
Lucentis is a humanized antibody fragment developed at Genentech and designed to bind and inhibit Vascular Endothelial Growth Factor A, a protein that is believed to play a critical role in angiogenesis, or the formation of new blood vessels.
NDLR : Actuellement il n'y a qu'un traitement Visudyne + laser qui permet de stabiliser l'état dans la dégénérescence maculaire (forme humide) qui est d'évolution assez rapide.
05/22/05 22:56 PM, EDT
Genentech Inc. said data from a Phase III clinical study showed that its investigational drug Lucentis maintained or improved vision in patients with wet age-related macular degeneration, which causes vision loss.
(...)
Lucentis is a humanized antibody fragment developed at Genentech and designed to bind and inhibit Vascular Endothelial Growth Factor A, a protein that is believed to play a critical role in angiogenesis, or the formation of new blood vessels.
NDLR : Actuellement il n'y a qu'un traitement Visudyne + laser qui permet de stabiliser l'état dans la dégénérescence maculaire (forme humide) qui est d'évolution assez rapide.